Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Macitentan, tadalafil combo found effective for newly diagnosed PAH

Publish date:: October 22, 2019

Key clinical point: Treatment with macitentan and tadalafil can elicit improvements in patients with newly diagnosed pulmonary arterial hypertension.

Major finding: There was a significant 47% reduction in pulmonary vascular resistance from baseline to week 16.

Study details: Phase 4 study of 46 patients.

Disclosures: Actelion Pharmaceuticals funded the trial. Dr. Sitbon disclosed relationships with Actelion, Bayer, GSK, Merck, Arena Pharmaceuticals, Gossamer Bio, and Ferrer.

Citation:

Sitbon O et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.825.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,